---
title: "UBS: HUTCHMED  Sovleplenib Approved in China for ITP and wAIHA Treatment, Positive and Better Than Expected"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306233318.md"
description: "UBS issued a research report on HUTCHMED, noting that its drug Sovleplenib received Chinese approval for ITP and wAIHA treatment. UBS views this as positive, exceeding expectations, as it is the first approved Syk inhibitor in China. The broker estimates peak sales of USD327 million by 2035, higher than market consensus, and maintains a 'Buy' rating with a HKD29.5 target price."
datetime: "2026-11-20T07:16:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306233318.md)
  - [en](https://longbridge.com/en/news/306233318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306233318.md)
generator: "portal-rs"
---

# UBS: HUTCHMED  Sovleplenib Approved in China for ITP and wAIHA Treatment, Positive and Better Than Expected

UBS released a research report stating that HUTCHMED (00013.HK) -0.500 (-2.328%) Short selling $6.57M; Ratio 21.740% 's Sovleplenib (a Syk inhibitor) received approval in China under priority review for the treatment of ITP and wAIHA. The broker viewed the development as positive and better than expected.

The broker noted that Sovleplenib is the first and only approved Syk inhibitor in China, with the approval supported by the ESLIM-01/02 studies. The broker estimated peak sales of USD327 million by 2035, compared with market expectations of USD241 million. The next key focus will be updates on overseas development strategies.

The broker maintained its "Buy" rating and HKD29.5 TP on HUTCHMED.

### Related Stocks

- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [HAWG.US](https://longbridge.com/en/quote/HAWG.US.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® | HCM Stock News](https://longbridge.com/en/news/305611428.md)
- [Citi Raises HUTCHMED  TP to HKD45.3, Maintains Buy/High Risk Rating and Top Pick Status](https://longbridge.com/en/news/306225953.md)
- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)
- [UBS: Positive SAFFRON and SANOVO Data for HUTCHMED  Show Potential of Savolitinib](https://longbridge.com/en/news/303166946.md)
- [HUTCHMED (China) Limited EMA, Japan Accept Reviews for Savolitinib + Osimertinib](https://longbridge.com/en/news/303871950.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**